公开(公告)号：US20200010904A1

公开(公告)日：2020-01-09

申请号：US16490143

申请日：2017-03-01

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Akihiro Ohashi ,  Kenichi Iwai ,  Tadahiro Nambu ,  Ryo Dairiki ,  Yuko Ishil

IPC: C12Q1/6886 ,  A61P35/00 ,  A61K31/519

Abstract: The present invention relates to a method of predicting the likelihood that a patient will respond therapeutically to a pancreatic cancer treatment comprising the administration of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one (Compound 1) and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof, comprising the steps of: STEP (1): determining a KRAS gene mutation status of a sample from a patient, and STEP (2): predicting an increased likelihood that the patient will respond therapeutically to the pancreatic cancer treatment if the patient has the presence of KRAS gene mutation(s), and to methods of treating pancreatic cancer.